The most significant market access barriers in Latin America are regulatory fragmentation, local testing and manufacturing requirements, pricing controls, and inconsistent intellectual property protections. These barriers vary considerably by country, meaning a product approved in one market may face entirely different hurdles in another. The sections below unpack each barrier in detail so companies can plan their regional strategy with clarity.
Which countries in Latin America have the most complex regulatory requirements?
Brazil, Mexico, and Argentina consistently present the most complex regulatory requirements for pharmaceutical and medical device market access in Latin America. Brazil’s ANVISA and Mexico’s COFEPRIS are among the most rigorous agencies in the region, with detailed dossier requirements, mandatory local testing provisions, and lengthy review timelines. Argentina’s ANMAT adds further complexity through its own distinct submission standards.
Beyond these three, Colombia (INVIMA), Chile (ISP), and Peru (DIGEMID) each operate independent regulatory frameworks with their own classification systems, language requirements, and technical standards. While some of these agencies have moved toward recognizing approvals from reference authorities such as the EMA or FDA, the degree of reliance varies significantly and is rarely automatic.
For companies entering the region, Brazil and Mexico typically require the most preparation time and resources. Brazilian registrations can take several years without a well-structured dossier, and COFEPRIS has strict requirements around local representation, labeling, and post-approval changes. Understanding which countries to prioritize and in what sequence is one of the most consequential early decisions a company can make. Our regulatory and market access services are specifically designed to help companies navigate these decisions with confidence.
Why does regulatory fragmentation slow down market entry across the region?
Regulatory fragmentation slows market entry in Latin America because each country operates its own independent regulatory system, with no unified regional authority equivalent to the EMA. A dossier accepted in Brazil cannot simply be resubmitted in Colombia or Chile without significant adaptation. This forces companies to run parallel submissions, manage multiple timelines, and maintain separate regulatory relationships across the region.
Unlike the EU, where a centralized procedure can cover 27 member states, Latin America has no equivalent mechanism. The Pacific Alliance (comprising Mexico, Colombia, Peru, and Chile) has made some progress toward regulatory harmonization, and PANDRH (the Pan American Network for Drug Regulatory Harmonization) continues to promote convergence, but practical alignment remains limited in 2026.
The practical consequence is that companies must often adapt their core technical dossier for each market, translate documents into Spanish or Portuguese, appoint local regulatory representatives, and respond to country-specific queries. This multiplies both the cost and the time to market, particularly for smaller companies without regional infrastructure already in place.
What are the local testing and manufacturing requirements in Latin America?
Several Latin American countries require local testing, local manufacturing involvement, or both as a condition of market authorization. Brazil, in particular, requires that imported products undergo batch release testing at a locally certified laboratory, and certain product categories face additional requirements for national production capacity. Mexico similarly mandates that some products include a local manufacturing or packaging step to qualify for registration.
Local batch release testing
ANVISA in Brazil requires that finished pharmaceutical products undergo quality control testing at a laboratory accredited within the country before they can be released to the market. This adds both time and cost to the supply chain and requires companies to establish relationships with Brazilian contract testing organizations or invest in local laboratory infrastructure.
Manufacturing and technology transfer requirements
Some countries, particularly Brazil under its produtiva nacional policies, have encouraged or required technology transfer agreements as part of registration or public procurement. This is especially relevant for biologics and vaccines, where government health programs represent a major share of the market. Companies targeting public tenders must often demonstrate a credible path toward local production or partnership with a Brazilian manufacturer.
How do pricing controls and reimbursement policies affect market access?
Pricing controls and reimbursement policies in Latin America can significantly limit commercial viability even after a product receives regulatory approval. Brazil, Mexico, and Colombia all have formal mechanisms for regulating pharmaceutical prices, and public reimbursement decisions are often separate from and slower than the registration process itself.
In Brazil, the CMED (Drug Market Regulation Chamber) sets maximum prices for pharmaceutical products, and companies must apply for price approval before commercializing. The pricing methodology considers factors such as international reference prices, therapeutic innovation, and budget impact. For products with limited clinical differentiation, the approved price may not support a commercially sustainable launch.
Colombia and Chile operate health technology assessment (HTA) processes that evaluate cost-effectiveness before determining reimbursement eligibility. In markets where public procurement dominates, as is the case for many essential medicines and biologics, a negative or delayed reimbursement decision can effectively block market access regardless of registration status. Companies should plan their pricing and market access strategy in parallel with their regulatory submission, not after it.
What intellectual property and data exclusivity challenges exist in Latin America?
Intellectual property protections and data exclusivity rights in Latin America are inconsistent across countries and generally weaker than in the EU or US. While most countries in the region are signatories to TRIPS, the implementation and enforcement of patent linkage, data exclusivity, and market exclusivity provisions vary widely and are frequently contested.
Brazil does not have a formal patent linkage system, meaning a generic or biosimilar applicant can receive regulatory approval even while an originator patent is still in force. Legal challenges must be pursued through the court system separately, which can be slow and unpredictable. Data exclusivity periods, where they exist, may not be consistently enforced or may be shorter than originator companies expect.
Argentina and Mexico have made some progress on patent linkage through administrative mechanisms, but enforcement remains a practical challenge. For biologics, the biosimilar regulatory pathways in the region are still maturing, and the standards for demonstrating biosimilarity vary. Companies launching innovative biologics should conduct a country-by-country IP assessment early in their regional strategy, as the risk profile differs substantially from one market to the next. To learn more about how we approach these assessments, visit our company page.
How can companies streamline regulatory submissions across Latin American markets?
Companies can streamline regulatory submissions across Latin America by building a modular, adaptable core dossier, prioritizing markets strategically, and engaging experienced local regulatory partners in each country. A well-structured dossier that anticipates the specific requirements of ANVISA, COFEPRIS, and ANMAT from the outset reduces the need for major rework at each submission stage.
Key strategies that support a more efficient regional approach include:
- Sequencing submissions strategically: Starting with Brazil or Mexico, where review times are longest, allows other markets to be progressed in parallel without delaying the overall regional timeline.
- Leveraging reference authority recognition: Several Latin American countries allow expedited review for products already approved by the EMA, FDA, or other reference authorities. Understanding which countries offer this pathway and under what conditions can significantly reduce review timelines.
- Appointing qualified local representatives early: Most countries require a local regulatory representative or importer of record. Identifying and onboarding these partners before submission avoids delays caused by administrative gaps.
- Standardizing core technical documents: A common technical dossier structure, adapted for regional requirements, avoids duplication of effort and ensures consistency across submissions.
- Monitoring regulatory updates proactively: Latin American regulatory agencies update their requirements regularly. Staying current with guideline changes from ANVISA, COFEPRIS, and others prevents submissions from being rejected on procedural grounds.
Working with a regulatory affairs partner who has direct experience across multiple Latin American markets can also reduce the learning curve considerably, particularly for companies entering the region for the first time.
How Starodub supports your market access strategy in Latin America
Navigating the regulatory barriers specific to Latin America requires both regional expertise and a structured approach to dossier preparation, submission sequencing, and local compliance. At Starodub, we work with biopharmaceutical and medical device companies to build practical, efficient pathways into Latin American markets, addressing the full range of barriers from regulatory fragmentation to pricing strategy.
Here is how we support companies entering or expanding across the region:
- Regulatory strategy and market sequencing: We assess your product profile and target markets to design a submission sequence that minimizes timelines and maximizes the use of reference authority recognition pathways.
- Dossier preparation and adaptation: We prepare and adapt technical dossiers to meet the specific requirements of ANVISA, COFEPRIS, ANMAT, INVIMA, and other national agencies, including translation coordination and local formatting standards.
- Local representative and partner coordination: We help identify and coordinate with qualified local representatives across key Latin American markets, ensuring your submissions meet administrative requirements from day one.
- IP and data exclusivity assessment: We provide country-by-country guidance on patent linkage, data exclusivity, and biosimilar regulatory pathways to inform your commercial and legal strategy.
- Post-approval compliance support: We support ongoing compliance requirements including labeling updates, post-approval change notifications, and renewal submissions to maintain your registrations across the region.
If you are planning to enter Latin American markets or looking to accelerate an existing regional program, contact us today to discuss how we can support your regulatory and market access strategy.
Related Articles
- What is the difference between PMDA and FDA approval processes?
- How do you build a global regulatory affairs strategy?
- What is regulatory affairs in pharmaceuticals?
- How do FDA and EU MDR requirements differ?
- What are the regulatory requirements for reprocessed single-use devices?
This content was generated with the help of AI — it may contain mistakes
